News Spark shares tank after haemophilia gene therapy safety sign... Biotech still pressing on with late stage trials
Partner Content Partner Content How challenges like Brexit & insufficient patients hinde... Challenges facing Orphan Drugs & Rare Diseases Research
Events Partner Content Orphan Drugs & Rare Diseases 2018 Orphan Drugs & Rare Diseases 2018 Conference
News NHS does not value CF patients, says Vertex CEO in letter to... But Vertex dismisses rumours it will quit the UK
Partner Content Partner Content Patient Organisations role in Orphan Drugs clinical developm... Orphan Drugs and Rare Diseases Conference - London
News Alexion hastens review of successor to rare disease blockbus... Alexion's rare disease drug Soliris is generating blockbuster-level sales – but the US biotech is rushing through development of a successor amid potential competition and U
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
